<DOC>
	<DOCNO>NCT00458913</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together cisplatin may kill tumor cell . PURPOSE : This phase II trial study side effect well give bortezomib together cisplatin work first-line therapy treat patient malignant mesothelioma .</brief_summary>
	<brief_title>Bortezomib Cisplatin First-Line Therapy Treating Patients With Malignant Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity safety bortezomib cisplatin first-line treatment patient malignant mesothelioma . - Validate use progression-free survival rate primary endpoint design phase II mesothelioma trial . OUTLINE : This nonrandomized , open-label , multicenter study . Patients receive cisplatin IV 1 hour day 1 bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 76 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pleural malignant mesothelioma , meet 1 follow criterion : Recurrent disease radical surgery Disease consider suitable radical treatment Measurable evaluable disease No clinical evidence brain leptomeningeal metastasis PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy &gt; 12 week Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Creatinine clearance &gt; 60 mL/min OR &gt; 50 mL/min ALT AST &lt; 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN liver metastasis present ) Bilirubin &lt; 1.5 time ULN No concurrent secondary malignancy except carcinoma situ cervix adequately treat basal cell skin cancer No malignancy treat within past 5 year Melanoma , breast cancer , hypernephroma treat within past 5 year without recurrence allow No uncontrolled severe cardiovascular disease , include follow : Myocardial infarction within past 6 month New York Heart Association class IIIIV heart failure Uncontrolled angina Clinically significant pericardial disease cardiac amyloidosis No infiltrative pulmonary pericardial disease No preexist peripheral neuropathy No known suspect allergy intolerance boron , mannitol , heparin , indwell catheter use No psychological , familial , sociological , geographical condition would preclude protocol compliance PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic chemotherapy mesothelioma No concurrent antineoplastic agent except medication may antineoplastic activity take reason ( e.g. , megestrol acetate , cyclooxygenase2 inhibitor , bisphosphonates ) No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
</DOC>